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Biomarkers and Preclinical Models
for Adult T-Cell Leukemia-Lymphoma
Treatment
Lee Ratner*
Division of Oncology, School of Medicine, Washington University in St. Louis, St. Louis, MO, United States
Adult T-cell leukemia/lymphoma (ATL) is an aggressive lymphoproliferative malignancy
with a very poor prognosis. Despite several recent advances, new therapeutic
approaches are critical, and this will require successful preclinical studies, including
studies in ATL cell culture systems, and mouse models. Identification of accurate,
reproducible biomarkers will be a crucial component of preclinical and clinical studies.
This review summarizes the current state-of-the-art in each of these fields, and provides
recommendations for future approaches. This problem is an important unmet need in
HTLV research.
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INTRODUCTION
Adult T-cell leukemia-lymphoma (ATL) is a refractory T cell malignancy. The most common
clinical variants, acute and lymphoma subtypes, are associated with a median survival of less
than 1 year (Katsuya et al., 2015). More indolent variants, smoldering and chronic ATL, are also
associated with poor prognoses, with median survivals of 2.6 and 4.6 years, respectively. In the
last several years, substantial progress was made in therapy for ATL. These achievements include
the following advances. First, established expert guidelines for the diagnosis and treatment of ATL
provide evidence-based recommendations for treatment (Cook et al., 2019). Second, aggressive
chemotherapy regimens have been shown to be superior to standard CHOP regimens for treatment
of the lymphoma subtype (Tsukasaki et al., 2007). Third, zidovudine plus interferon with or without
arsenic trioxide has shown strong responses in the acute subtype of ATL (Bazarbachi et al., 2010).
Fourth, allogeneic stem cell transplant has demonstrated potential for cure in eligible subjects
(Hishizawa et al., 2010). Fifth, mogamulizumab has shown significant activity in multiple ATL
subtypes (Ishida et al., 2015). Sixth, lenalidomide has also shown activity in relapsed and refractory
subtypes of ATL (Ishida et al., 2016).
Despite, these advances, the prognosis of ATL remains quite poor. Advances in treatment require
the establishment of biomarkers for response predictions. Moreover, improved preclinical models
are required for identifying potentially active therapies. The focus of this review is to assess the
current status of ATL biomarkers and preclinical models for improving ATL therapy.
BIOMARKERS FOR ATL
Cancer biomarkers refer to a substance or process that is indicative of the presence of cancer in
the body (Goossens et al., 2015). A biomarker may be a molecule secreted by a cancer, or a specific
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response of the body to the presence of the tumor. Genetic,
epigenetic, proteomic, and imaging biomarkers can be used for
cancer diagnosis, prognosis, or treatment predictions. For the
purpose of the current review, we are focused on biomarkers
that may provide a quantifiable and accurate predictive measure
of ATL response or lack of response to therapy. Ideally, the
same biomarker can be used in preclinical and clinical studies. If
biomarkers can be identified that are highly predictive of changes
in tumor load in patients as well as patient survival, they can
assist in defining the mechanism of action of a therapy and/or
validating that the intended target is inhibited. In addition, the
identification of predictive biomarkers can reduce the cost and
duration of future preclinical and clinical studies, and improve
safety by decreasing the duration of exposure to ineffective and
potentially toxic therapies.
Major prognostic indicators for ATL were defined in a study
of 854 patients with ATL (Tsukasaki et al., 2009). The parameters
identified by multivariate analysis to have prognostic potential
were poor performance status, high lactic dehydrogenase (LDH)
levels, age greater than 40 years, more than three involved
lesions, and hypercalcemia. Using these factors, a risk model was
constructed that may have applications for individual patients.
Additional factors associated with a poor prognosis include
thrombocytopenia, eosinophilia, bone marrow involvement,
high interleukin 5 (IL5) levels in the serum, CC-chemokine
receptor 4 (CCR4) expression, lung-resistance-related protein,
p53 mutation, and p16 deletion (Tsukasaki et al., 2009). Several
markers have also been used to define poor risk chronic ATL
(Katsuya et al., 2017).
The proviral DNA level (PVL) may provide prognostic and/or
predictive information (Iwanaga et al., 2010). Quantitation
of proviral levels in peripheral blood mononuclear cells is
performed by quantitative PCR methods, by comparison with
a cellular gene (Brunetto et al., 2014). The presence of a single
provirus per infected cell allows one to use PVL as a measure of
the number of infected cells (Cook et al., 2014). Levels of PVL
have been used to follow patients after allogeneic hematopoietic
stem cell transplants for ATL (Shiratori et al., 2008). However, it
must be recognized that PVL measures the number of infected
cells rather than number of malignant cells. Most assays have
utilized the tax gene for PCR amplification. Moreover, the
number of proviruses per peripheral blood mononuclear cell
(PBMC) may be higher in acutely infected cells as compared
to chronically infected cells. It must also be kept in mind
that PBMCs include B lymphocytes, and CD8+ lymphocytes in
addition to CD4+ lymphocytes. Although CD4+ lymphocytes
are the predominant infected cell in vivo, significant viral
loads can be detected in CD8+ lymphocytes, which are rarely
transformed by HTLV-1 (Goon et al., 2002). In addition, although
the primers for PCR are typically based on highly conserved
HTLV-1 sequences, polymorphisms, mutations, or deletions
within tax would affect PVL measurements. Lastly use of a
cellular gene as a control may be problematic given high levels
of aneuploidy associated with ATL, which may affect the copy
number of the chosen cellular gene (Kamihira et al., 1994).
Cell-free circulating tumor DNA (cfDNA) has been used
to monitor tumor load in a number of types of malignancies
(Corcoran and Chabner, 2018). The precise mechanism of
release of cfDNA is unclear. Biological processes suggested to
be involved include apoptosis and necrosis from dying cells,
or active release from viable tumor cells. The typical size of
fragmented cfDNA is 166 base pairs, which corresponds to the
length of DNA wrapped around a nucleosome plus a linker
(Cole et al., 2016). Various techniques have been proposed for
collection, extraction, and analysis of cfDNA (Stewart and Tsui,
2018). A recent abstract presentation described the application
of this methodology for monitoring HTLV-1 infection (Haddow
et al., 2019). In this study, plasma DNA was isolated as well as
genomic DNA from PBMCs from 36 subjects. HTLV-1 DNA was
detectable by qPCR in 30 of 36 samples with 0–31 copies of tax/ml
plasma (P-cfDNAPVL). A strong correlation was found between
P-cfDNAPVL and PBMC-PVL. It should be noted, however, that
none of the individuals participating in this study had ATL.
Cell-associated HTLV-1 RNA may also be used to quantify
virus gene expression (Yamano et al., 2002). Since helix basic
zipper gene (HBZ) is continuously expressed in HTLV-1 infected
individuals, it is predicted that levels of hbz mRNA may correlate
well with virus load (Mitobe et al., 2015). Since tax is generally
not expressed or only transiently expressed in ATL, detection
of tax RNA in PBMCs may provide a measure of plus strand
expression (Kataoka et al., 2015). Levels of tax RNA in PBMCs
may be elevated in acutely infected cells, or in cells manifesting
virus re-activation from latency. Another measure of active virus
replication is the level of 1- or 2-LTR circles (Sloan and Wainberg,
2011). These are considered by-products of reverse transcription
and entry of preintegration complexes in the nucleus. The 1- or
2-LTR circles are thought to form as a result of recombination
and/or ligation in the nucleus, but are not likely to be templates
for integration (Bukrinsky et al., 1993). In one study of HTLV-1
LTR circles, 1-LTR circles were detected in 14 of 20 patients at a
mean of 1.38 copies/100 PBMCs. The 2-LTR circles were detected
in 30 of 31 patients (Fox et al., 2016).
HTLV-1 infected cells may increase in an individual through
(1) retrovirus replication, virus release, and infection of new
target cells, and/or (2) clonal expansion of infected cells
carrying an integrated provirus that undergo mitotic cell division
(Bangham and Ratner, 2015). Although HTLV-1 integrates at
a wide range of different sites in the human genome, with
limited preference for specific genetic features, ATL cells within
an individual are in 91% of cases, characterized by a predominant
single integration site (Cook et al., 2014). In 24% of ATL
cases an intermediate abundance clone is present. This was
first identified by Southern blot analysis of HTLV-1 provirus
integration, and more recently by next-generation sequencing
methods of integration sites (Yamaguchi et al., 1984; Gillet
et al., 2011). Alternatively, variant allele frequency measurements
of specific ATL genetic abnormalities provide an alternative
measurement of clonal outgrowth of ATL (Farmanbar et al.,
2018). Laydon et al. (2014) and Farmanbar et al. (2019) also
reported quantification of HTLV-1 clonality using TCR diversity
analysis. However, we have identified subjects in whom two or
more TCR gene rearrangements are present within a population
of ATL cells with a single proviral integration site (Rauch et al.,
2019). Moreover, intratumor heterogeneity has been shown to
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be a complex and early event in the development of ATL
(Farmanbar et al., 2018).
Cell surface marker analysis may also be used to monitor
tumor load. Levels of survivin, a member of the inhibitor of
apoptosis (IAP) family was reported to be predictive of clinical
response to proteasome inhibitor bortezomib or anti-CD25
antibody, daclizumab (Pise-Masison et al., 2009). More recently, a
multicolor flow method has been described as a useful technique
to monitor ATL cells in infected patients. For this purpose,
Kobayashi et al., showed that CD4 cells expressing cell adhesion
molecule-1 (CADM1), but with reduced expression of cell surface
co-stimulatory protein, CD7 represent transformed cells. More
recently, CD45RA+ T memory stem (TSCM) cells were identified
as cancer initiating cell capable of reconstituting ATL clones
(Nagai et al., 2015).
Several serum markers have also been used as prognostic or
predictive markers. The α-chain of the interleukin 2 receptor
(IL-2R; CD25) is over-expressed on ATL cells, and sIL-2R have
been used to monitor disease, particularly in Japanese patients
(Katsuya et al., 2012, 2017). The soluble form of IL-2R is released
as a result of proteolytic shedding from activated T cells. Levels
of sIL-2R was reported to be a poor prognostic marker in a
wide range of B cell lymphomas (Kusano et al., 2017). CD30 is
a member of the tumor necrosis factor (TNF) receptor family
that is expressed on activated, but not resting T and B cells,
and is associated with signal transduction that leads to activation
of nuclear factor kappa B (NFκB). Elevated levels of soluble
CD30 are also linked with various T-cell neoplasms, including
ATL (Nishioka et al., 2005). OX-40 is another member of the
TNF receptor superfamily, that co-stimulates activated T cells
following interaction with its own ligand. High levels of OX40
have also been reported as a marker of ATL (Tanaka et al.,
2019). Lastly, plasma-associated exosomes may also be useful for
monitoring HTLV-1 infection (Jeannin et al., 2018).
In summary, numerous potential biomarkers for ATL
have been proposed, but systematic comparison and analysis
of their utility in monitoring treatment response remains
to be performed.
CELL CULTURE MODELS WITH ATL
CELLS
Numerous studies have used HTLV-1 infected cell lines for
preclinical evaluation of potential anti-ATL therapies. However,
it is unclear whether these cell lines recapitulate the key
oncogenic features of ATL. HTLV-1 infected cell lines have
been subdivided into Tax-expressing (Tax+) and Tax non-
expressing (Tax−) cell lines. It is generally believed that Tax
expression is lost in ATL (Kataoka et al., 2015). This has
been attributed to escape from immunosurveillance (Hanon
et al., 2000). Tax is an important target of CTL responses to
ATL. Moreover, Tax expression is associated with expression of
other plus strand HTLV genes, which also contribute to ATL
immune responses (Bangham and Osame, 2005). Alternatively,
Tax has been implicated in the induction of cellular senescence
through NFκB hyper-activation (Zhi et al., 2011). Repression
of Tax has been suggested as a means of overcoming this
inhibitory activity.
Molecular mechanisms that account for loss of Tax expression
in 50% of ATL cases include deletions in the integrated provirus
in ATL cells, DNA methylation, and/or chromatin modifications
associated with epigenomic shut-off of the HTLV-1 genome
(Takeda et al., 2004; Taniguchi et al., 2005). It has been suggested
that tumors capable of expressing Tax compared to those unable
to express Tax, may represent two biologically distinct subtypes
of ATL, perhaps analogous to the different latency programs in
EBV-associated malignancies (Mahgoub et al., 2018).
Tax has been suggested to be an ATL initiation factor, but it
is unclear whether it is required for ATL maintenance (Baratella
et al., 2017). It is possible that HBZ is a tumor maintenance
factor. HBZ has weak tumorigenic activity, and is continuously
expressed in HTLV-1 infected cells in patients (Mitobe et al.,
2015; Esser et al., 2017).
Transient expression of Tax from a minority of cells in culture
was shown to occur in certain ATL cell lines and primary T cell
cultures from HTLV-1 infected patients (Mahgoub et al., 2018).
In the MT1 cell line, Mahagoub et al., showed that 0.05–3.0% of
cells with bursts of Tax expression at any time, lasting on average
19 hrs. During Tax expression, antiapoptotic and NFκB-related
genes were expressed. Moreover, they showed upregulation of Tax
expression by cytotoxic stress, such as oxidative stress. Repression
of Tax expression with siRNA resulted in apoptosis of the culture.
Billman et al. (2017) showed similar bursts of Tax expression
in T cell clones from HTLV-1 infected subjects. Using single
molecule FISH, they found that 1-10% of cells expressed Tax.
Moreover, cells expressing Tax did not express HBZ. In addition,
to cellular stress, they found that hypoxia or glucose metabolism
also enhanced Tax expression.
Based on these observations, it is recommended that
preclinical studies demonstrate activity in ATL cell lines which
are Tax-independent, as well as cell lines that are Tax-
dependent with transient bursts of Tax. However, it should
be noted that improved characterization of ATL cell lines is
required. Do these cell lines fully recapitulate the biological and
molecular characteristics of ATL in the patients from which
they were derived? What cultures conditions provide the closest
representation of ATL? Are these characteristics representative
of all ATL disease subtypes? Are there specific characteristics
that differentiate ATL cells derived from smoldering or chronic
subtypes of ATL from acute or lymphoma subtypes? Can these
ATL cell lines recapitulate key features of the disease when
inoculated into an animal model?
MOUSE MODELS OF ATL
Although rats, rabbits, and monkeys have been used in a small
number of preclinical models for ATL, the majority of studies
have utilized various mouse models (Lairmore et al., 2005).
However, HTLV-1 does not infect or replicate in murine cells.
Blocks are present at the level of viral entry and Tax expression,
and perhaps other steps in virus replication (Trejo and Ratner,
2000). Thus, an ideal animal model for preclinical studies of
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HTLV-associated tumors is still lacking. This is particularly
important in studies of immune therapies, where distinct features
of the microenvironment play a critical role in efficacy.
Genetically engineered mouse (GEM) models provide
valuable tools for cancer research (Richmond and Zu, 2008).
An advantage of such models is that they allow analysis of
many genetic backgrounds using a variety of mouse strains.
In addition, the tumor exists in the presence of a competent
immune system. These models allow definition of mutations
that mimic those identified in human tumors. In addition, they
allow one to follow tumor development from early time points.
Disadvantages include the fact that a limited number of genes
may not reflect the complex heterogeneity of human tumor cells,
they are costly and time consuming, and tumor development is
often slow and variable.
Several different GEM models have been developed with
Tax and/or HBZ, resulting in lymphoproliferative disease
(Zimmerman et al., 2011). Ratner et al., expressed Tax with
the human granzyme promoter (Grossman et al., 1995). These
mice have been engineered with a marker to monitor Tax level
non-invasively, which led to observations of dynamic changes in
Tax levels over time and induction with various inflammatory
stimuli (Rauch et al., 2009a,b). Greene et al., reported on an
inducible Tax murine model using EmuSR alpha promoter and
a doxycycline-repressible enhancer (Kwon et al., 2005). These
mice developed polyclonal lymphocytic inflammation in the skin.
Hasegawa et al. (2006) expressed Tax in developing thymocytes
using the Lck proximal promoter. After 10 months, the majority
of these mice developed hepatomegaly and mesenteric tumors,
characterized as diffuse large-cell lymphomas. All of these models
demonstrated dependence on NFκB activation (Portis et al.,
2001; Kwon et al., 2005; Hasegawa et al., 2006). Injection of the
Tax transgenic cells from Hasegawa’s transgenic mice into SCID
mice resulted in an aggressive leukemia characterized by “flower”
cells, as well as extensive lymph node and skin involvement,
similar to the transgenic mice. Cancer initiating cells isolated
from these tumors reproduced the disease phenotype (Yamazaki
et al., 2009). Treatment of transgenic mice with arsenic and
interferon, resulted in Tax protein degradation, and depletion
of cancer initiating cells (ElHajj et al., 2010). Bellon et al.
(2016) used xenografts from these Tax transgenic tumors to
study the anti-proliferative activity of Pim1 kinases inhibitors.
ElHajj et al. (2014) showed that synthetic retinoids inhibited
Tax transgenic tumor cell growth and induced apoptosis in NSG
mice. They ascribed this effect to enhanced degradation of Tax.
HBZ transgenic mice also develop lymphoid malignancies, but
with a longer latency than Tax transgenic animals, and with an
incomplete penetrance (Satou et al., 2011; Esser et al., 2017).
Xenografts of human tumor cell lines in mice (CDX models)
have provided valuable models for screening and evaluation
of candidate anticancer drugs (Richmond and Zu, 2008). Such
models can predict the drug response of a tumor in human
patients, and are rapid. The major disadvantage is that the
mice are immunocompromised, thus, obscuring the effect of
the microenvironment. The severe combined immunodeficiency
(SCID) mouse was developed in the 1980s, and has been
commonly used for xenograft studies of cancer. Although the
non-sense mutation in the protein kinase DNA-activated catalytic
polypeptide (Pkrdc) results in loss of B and T lymphocytes
in these mice, they retain normal macrophage, dendritic, and
natural killer cell functions (Zimmerman et al., 2011). Several
different ATL cell lines have been engrafted successfully into
SCID mice, including Hut 102, RV-ATL, and SLB-1 cells. Further
refinements of the mouse models have incorporated into SCID
mice, various defects of innate immune function. These include
SCID/beige and NOD/SCID mice, with or without mutations
of IL-2Rγ. Ishitsuka et al. (2012) used SCID mice inoculated
subcutaneously with Hut 102 cells to assess the activity of the
pro-apoptosic drug ABT-737. Maeda et al. (2010) used non-
obese diabetic (NOD)/SCID mice injected with Hut 102 cells,
to assess growth inhibitory activity of anti-CD30 monoclonal
antibodies. Ishikawa et al. (2018) used SCID mice inoculated with
Hut 102 cells to demonstrate the effects of inhibitors of mTOR
and/or PI3K. Tsumuraya et al. (2011) used SCID mice inoculated
with Hut 102 cells to demonstrate inhibition of hippuristanol,
a polyoxygenated steroid. They ascribed this effect to inhibition
of eukaryotic initiation factor eIF4A. Other studies with Hut102
cells in SCID mice have examined NFκB inhibitors curcurmin,
dehydroxymethyl epoxyquinomicin (HDMEQ), and synthetic
retinoid NIK-333, mevalonate pathway inhibitor incadronate,
combined NFκB and AP-1 inhibitors carotenoid fucoxanthinol,
modified galectin hG9NC, and retinoic acid receptor inhibitor
tamibarotene (Zimmerman et al., 2011). Additional studies have
used MT1, MT2, and TL-Om1 cells to study effects of DHMEQ,
and MET-1 cells to examine the effects of IL-2R monoclonal
antibody, anti-CD52 antibody campath-1H, anti-CD2 antibody
MEDI-507, and flavoperidol (Zimmerman et al., 2011). More
recently, Zhang et al. (2015) used EC40515(+) cells to study the
activity of JAK inhibitors on subcutaneous growth in NOD/SCID,
IL2Rγnull (NSG) mice.
Patient-derived xenograft (PDX) models provide a powerful
tool to investigate tumor biology and preclinical activity of
potential therapies (Jung et al., 2018). PDX models have the
advantage over CDX models in providing cancer-associated
stromal cells with primary tumors which may provide a more
realistic heterogeneity of tumor cells (Richmond and Zu,
2008). Their major shortcoming is that they are expensive
and technically complicated. Kondo et al. (1993) demonstrated
successful xenotransplantation into SCID mice of PBMCs from
six of eight ATL subjects. Similar models have been used by
other investigators subsequently (Phillips et al., 2000; Kawano
et al., 2005). Nakamura et al. (2015) reported on the use of
NOD/SCID mice null for Jak3 injected with primary PBMCs
from ATL patients. The malignant cells were serially transplanted
between animals. They used this model to demonstrate activity of
the anti-oxidant, pyrrolidine dithiocarbamate (PDTC). In recent
work, Xiang et al. (2019) described the development of ATL in
mice injected with purified CD4+ cells from patients with ATL in
NSG mice, but not with total PBMCs. The latter finding suggests
that non-CD4+ cells antagonize ATL development in this model.
NSG mice have been humanized with hematopoietic stem cells
isolated from umbilical cord PBMCs based on their expression of
CD34 or CD133 (Villaudy et al., 2011; Ikebe et al., 2013; Tezuka
et al., 2014). These mice can then be infected by inoculation
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of irradiated HTLV-1 producer cells. After 6–12 weeks, these
animals develop an aggressive lymphoproliferative disorder
with many of the manifestations of human ATL, including
flower cells, visceral infiltration of CD4+ cells, lytic bone
lesions, hypercalcemia, and oligoclonal expansion of infected
cells (Villaudy et al., 2011; Tezuka et al., 2014; Xiang et al., 2019).
These models have the advantage that they can examine effects
of drugs on HTLV-1 replication in vivo. However, these models
have the disadvantage of long duration and variable levels of
humanization, incomplete disease penetrance, and variable levels
of virus replication.
CONCLUSION
Further studies of biomarkers, cell culture and animal
models of ATL are very important to develop improve
therapies for this devastating malignancy. Critical analysis
of each assay and model in preclinical vs. clinical studies
of new therapeutic approaches is warranted. Strengths
and weaknesses of each approach should be analyzed,
compared, and validated.
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